Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.

Department of Pathology and Comprehensive Cancer Center, Department of Pediatrics, The University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
Journal of Biological Chemistry (Impact Factor: 4.65). 07/2001; 276(22):19012-9. DOI: 10.1074/jbc.M009984200
Source: PubMed

ABSTRACT At least two distinct recurrent chromosomal translocations have been implicated in the pathogenesis of MALT lymphoma. The first, t(1;14), results in the transfer of the entire Bcl10 gene to chromosome 14 wherein Bcl10 expression is inappropriately stimulated by the neighboring Ig enhancer. The second, t(11;18), results in the synthesis of a novel fusion protein, API2-MALT1. Until now, no common mechanism of action has been proposed to explain how the products of these seemingly unrelated translocations may contribute to the same malignant process. We show here that Bcl10 and MALT1 form a strong and specific complex within the cell, and that these proteins synergize in the activation of NF-kappaB. The data support a mechanism of action whereby Bcl10 mediates the oligomerization and activation of the MALT1 caspase-like domain. This subsequently activates the IKK complex through an unknown mechanism, setting in motion a cascade of events leading to NF-kappaB induction. Furthermore, the API2-MALT1 fusion protein also strongly activates NF-kappaB and shows dependence upon the same downstream signaling factors. We propose a model whereby both the Bcl10.MALT1 complex and the API2-MALT1 fusion protein activate a common downstream signaling pathway that originates with the oligomerization-dependent activation of the MALT1 caspase-like domain.

  • [Show abstract] [Hide abstract]
    ABSTRACT: B-cell CLL/lymphoma 10 (BCL10) is crucial for the activation of NF-κB in numerous immune receptor signaling pathways, including the T-cell receptor (TCR) and B-cell receptor signaling pathways. However, the molecular mechanisms that lead to signal transduction from BCL10 to downstream NF-κB effector kinases, such as TAK1 and components of the IKK complex, are not entirely understood. Here we used a proteomic approach and identified the E3 ligase MIB2 as a novel component of the activated BCL10 complex. In vitro translation and pulldown assays suggest direct interaction between BCL10 and MIB2. Overexpression experiments show that MIB2 controls BCL10-mediated activation of NF-κB by promoting autoubiquitination and ubiquitination of IKKγ/NEMO, as well as recruitment and activation of TAK1. Knockdown of MIB2 inhibited BCL10-dependent NF-κB activation. Together, our results identify MIB2 as a novel component of the activated BCL10 signaling complex and a missing link in the BCL10-dependent NF-κB signaling pathway.
    Journal of Biological Chemistry 09/2011; 286(43):37147-57. · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: T lymphocytes are critical mediators of adaptive immunity that recognize antigen through the T cell receptor (TCR). Stimulation of the TCR leads to a complex signal transduction cascade resulting in the activation of the transcription factors NFAT, AP-1 and NF-kappaB. The activation of these transcription factors is a crucial step in T lymphocyte activation. TCR stimulation results in the spatial redistribution of several proteins involved in signal transduction to NF-kappaB. We find that the signaling intermediate Bcl10 forms cytoplasmic oligomers, called POLKADOTS, upon antigen stimulation. The formation of these structures requires the interaction between Bcl10 and MALT1 and is correlated with the activation of NF-kappaB. Our research shows that POLKADOTS are foci for functional interactions between signaling intermediates in TCR-mediated activation of NF-kappaB. In addition to forming POLKADOTS in the cytoplasm in response to antigen signals, a significant portion of cellular Bcl10 localizes to the nucleus in the steady state. Observations of high enrichment of Bcl10 in the nucleus of MALT lymphoma tumor cells suggest that Bcl10 nuclear localization may be actively regulated by signaling processes. Aberrant redistribution of Bcl10 to the nucleus in MALT lymphomas may contribute to tumorigenesis or pathogenesis. We show that Bcl10 is found in the nucleus of T lymphocytes, that this localization is regulated by PKCtheta, and that dose-dependent interactions with MALT1 mediate the nuclear export of Bcl10. We also show that the N-terminus of Bcl10 is essential for NF-kappaB activation, possibly by functioning as a transcriptional enhancer for NF-kappaB-responsive genes. These results may further suggest a pathogenic role for nuclear localization of Bcl10 in MALT lymphomas. In summary, through spatial-temporal analysis of Bcl10 subcellular localization and protein-protein interactions, we have further elucidated the role played by Bcl10 in health and in disease.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The paracaspase MALT1 is a Cys-dependent, Arg-specific protease that plays an essential role in the activation and proliferation of lymphocytes during the immune response. Oncogenic activation of MALT1 is associated with the development of specific forms of B-cell lymphomas. Through specific cleavage of its substrates, MALT1 controls various aspects of lymphocyte activation, including the activation of transcriptional pathways, the stabilization of mRNAs, and an increase in cellular adhesion. In lymphocytes, the activity of MALT1 is tightly controlled by its inducible monoubiquitination, which promotes the dimerization of MALT1. Here, we describe both in vitro and in vivo assays that have been developed to assess MALT1 activity.
    Methods in molecular biology (Clifton, N.J.) 01/2014; 1133:177-88. · 1.29 Impact Factor